StockpollyBeta
Get App
Popularity #2,644
AURA · NASDAQ · Biotechnology

Aura Biosciences (AURA)

Develops bel-sar, a virus-like drug conjugate for organ-preserving cancer treatment.

$6.01
vs last close−0.44 (−6.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
202522232328292828273548
Research & development152017171722232322222831
5556656665717
Selling & marketing000000000000
General & administrative5556656665717
Other expenses000000000000
Operating income−20−25−22−23−23−28−29−29−28−27−35−48
233222222212
Interest income233222222212
Other non-operating income0−3−3−2−20−2−2−2−2−10
Income before tax−19−22−20−20−21−26−27−27−26−26−34−46
Income tax expense000000000000
Net income from continuing operations−19−22−20−20−21−26−27−27−26−26−34−46
Net income−19−22−20−20−21−26−27−27−26−26−34−46
EPS, basic−$0.48−$0.50−$0.40−$0.41−$0.42−$0.52−$0.55−$0.47−$0.40−$0.40−$0.50−$0.48
EPS, diluted−$0.48−$0.50−$0.40−$0.41−$0.42−$0.52−$0.55−$0.47−$0.40−$0.40−$0.50−$0.48
Weighted average shares, basic384449505050505866606795
Weighted average shares, diluted384449505050505866606795
EBITDA−20−22−19−20−21−28−27−27−26−25−32−48
Depreciation & amortization000000000010
EBIT−20−22−20−20−21−28−27−27−26−26−34−48